Search

everythinglearnresearchcommunity

for

Search:↓

Topical human epidermal growth factor may effectively treat acne caused by cancer medication.

Acneiform follicular mucinosis can be controlled with systemic corticosteroids.

Chronic cutaneous lupus erythematosus should be considered when acne treatments don't work.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.

A patient's skin eruption was caused by the cancer drug cyclophosphamide and improved after stopping the drug.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

EGFR inhibitors often cause skin problems and other side effects, but these are usually reversible and can be managed to keep patients comfortable.

Some medications can cause acne, and stopping these drugs is the main treatment.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.

The document talks about hard-to-treat and rare acne types, their connection with other health issues, the importance of correct diagnosis, and the challenges in managing them.

Non-ablative fractional laser treatments have a low risk of side effects in Asian patients.

Oral mTOR inhibitors often cause skin and hair side effects but usually don't require stopping treatment.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

EGFR inhibitors can cause yellowish skin eruptions.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

Skin problems from transplant drugs are common and need careful management in organ transplant patients.

Some cases of folliculotropic mycosis fungoides may progress slowly and not need aggressive treatment.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Isotretinoin effectively treated severe acne in HIV-positive women, with improved skin and CD4 counts, but some experienced side effects like skin dryness and hair loss.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

Skin side effects from cancer treatments can lead to changes in therapy and are common, with nail changes being the most frequent.

A 21-year-old had a rare developmental anomaly with a misplaced sebaceous gland in a hair follicle.

Mexican patients had a lower incidence of skin reactions to drugs and no significant link between these reactions and the TNF2 gene variant.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

Intramuscular corticosteroids are effective and safe for severe alopecia areata, with most patients regrowing hair, but nearly half may relapse.

Skin reactions are a common reason for emergency visits due to drug allergies, with some severe cases needing intensive care.

Understanding how acne develops in different diseases could lead to new treatments.